Ask AI
ProCE Banner Series

IDHentifying Appropriate Patients With MDS or AML to Treat With TIBSOVO®

Key Takeaways

  • Review treatment considerations in MDS and ML, including the role of IDH1 and the importance of molecular testing for treatment planning.
  • Review barriers, treatment considerations, clinical efficacy, safety, and real-world evidence supporting Tibsovo + Aza for IC-ineligible mIDH1+AML, along with case studies in newly diagnosed patients.
  • Choose to review MDS classification, considerations and the clinical efficacy and safety profiles that supports the use of Tibsovo in adult patients with relapsed refactory mIDH1+MDS

All Events

IDHentifying Appropriate Patients With MDS or AML to Treat With TIBSOVO®

Upcoming Events

October

27

2026

12:15 PM - 1:15 PM Eastern Time (ET)

Virtual

Additional Info

Acknowledgement

Sponsored By

Servier Pharmaceuticals

Servier Pharmaceuticals